CANNDOC Pharma

Provider of pharma-grade treatments for patients by using medical cannabis.

Health Tech & Life Sciences
Acquired by InterCure
Acquired Herzliya, Israel Founded 2008
Last updated 2026-07-22
Total raised
$12.0M
Stage
Acquired
Founded
2008
Headcount
8
HQ
Herzliya, Israel
Sector
Health Tech & Life Sciences

About

CANNDOC Pharma is a pioneer in the medical cannabis industry, developing and providing pharma-grade cannabis solutions to achieve better patient health and therapy. The company focuses on validating clinical significance through trials with hospitals and universities, and its products are held to the highest pharmaceutical standards, meeting global Good Manufacturing Practice (GMP) regulatory requirements. CANNDOC offers products for various diseases like neuropathic pain, relief of pain of cancerous source, inflammatory bowel disease, post-traumatic stress disorder, Parkinson's, and epileptic seizures. Canndoc has been pioneering Pharma-Grade cannabis for more than 15 years, providing millions of doses to 40,000 patients.

Funding history · 1 round · $12.0M total

2018-11
Undisclosed Round $12.0M NoCamels, Nov 2018
Alex RabinovichGMF Capital

Headcount over time

From 11 (2019-11) to 7 (2025-10) · -4 (-36%) · 15 points · source: Finder history + radar grounding
120 2019-11 2025-10

Q&A

What is CANNDOC Pharma's primary business?
CANNDOC Pharma develops pharma-grade cannabis products, focusing on research, cultivation, processing, and product development, with a GMP clinical trial pipeline.
When was CANNDOC Pharma founded?
CANNDOC Pharma was founded in January 2008.
Who acquired CANNDOC Pharma and when?
CANNDOC Pharma was acquired by InterCure in September 2018.
What is the employee count of CANNDOC Pharma?
CANNDOC Pharma has 1-10 employees.
What medical conditions do CANNDOC Pharma's products address?
CANNDOC Pharma's GMP-standard products are prescribed for conditions such as neuropathic pain, cancer pain, inflammatory bowel disease, post-traumatic stress disorder, Parkinson's disease, and epileptic seizures.
In which countries are CANNDOC Pharma's products and genetics regulated?
CANNDOC Pharma's products and genetics comply with regulatory requirements in Europe, Canada, and Israel.
Who is the CEO of CANNDOC Pharma?
Alexander Rabinovitch is the CEO of CANNDOC Pharma.
What is the primary sector of CANNDOC Pharma?
CANNDOC Pharma's primary sector is Health Tech & Life Sciences.

Team · 1

Barak
Founder · Founder

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyMedical Cannabis
Technologies
Materials & SubstancesRaw MaterialsBiologicalsGenes
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2GB2B

Highlights

1 Patents

Tags

cancertherapeuticsparkinsonepilepsygeneticspain-reliefoncologyinflammatory-diseasescannabismedical-cannabisoral-drugspharmaceuticals
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websitecanndoc.com/
LinkedInlinkedin.com/company/13028545

Identifiers & details

Legal nameCanndoc Ltd.
Founded2008
Employees (exact)8
Status reasonAcquired by InterCure on Sep 2018

Acquisitions & public offerings

Acquired by InterCure 2018-09

Radar intelligence

Web history (Wayback)

Domaincanndoc.com

Certificate / subdomain footprint

Subdomains2

Israeli Companies Registrar (רשם החברות / ICA)

Registrar # (ח.פ.)514418581
Statusפעילה
Corp typeישראלית חברה פרטית
Incorporated2010-03-07
Purposeלעסוק בכל עיסוק חוקי
Liabilityמוגבלת
In violation (unfiled)no
Last annual report2024
Active charges / liens0
Registry events0
Registered addressמדינת היהודים 85 הרצליה